Business
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
MHRA seeks to harmonize UK & US regulatory review via Project OrbisEMA Rapporteur Scientific Advice Meeting scheduled for October 2025New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it held a successful Scientific Advice Meeting with the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agen
About this update from Os Therapies Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"MHRA seeks to harmonize UK & US regulatory review via Project Orbis","length":71,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"EMA Rapporteur Scientific Advice Meeting scheduled for October 2025","length":67,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":138,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it held a successful Scientific Advice Meeting with the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) in July and has submitted an invited Innovative Licensing and Access Pathway (ILAP) application to begin the regulatory process towards approval of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. MHRA suggested applying for Project Orbis at the time of regulatory approval submission to synchronize its Marketing Authorization Application process with the United States Food & Drug Administration's (FDA) Biologics Licensing Application (BLA) Accelerated Approval Program. In addition, a European Medicines Agency rapporteur, the Netherlands Medicines Evaluation Board (MEB) granted the Company a SAM meeting to begin the requisite processes towards a European Union-wide Marketing Authorisation via the Centralised Procedure.","length":1187,"tagName":"p"},{"type":"text","content":""We are pleased with the outcome of our meeting with MHRA in the UK and are working to ensure that we provide FDA and MHRA everything they need to be able to rapidly approve OST-HER2 for metastatic osteosarcoma patients," said Paul Romness, MPH, CEO of OS Therapies. "We have officially begun the regulatory process in Europe as the next part of our regulatory strategy to bring this novel immunotherapy to osteosarcoma patients worldwide."","length":460,"tagName":"p"},{"type":"text","content":"Project Orbis is an innovative global initiative designed to facilitate international collaboration in the field of oncology. Launched by the U.S. Food and Drug Administration (FDA), this program seeks to streamline the process...